Recent Updates
Recently added Catalysts
MLTX Negative Sentiment Score: 25/100

MoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MLTX

Key Takeaway: MoonLake Immunotherapeutics is facing a class action securities lawsuit, as announced by Levi & Korsinsky, LLP. The lawsuit pertains to claims of securities fraud affecting investors from March 10, 2024, to September 29, 2025. Key allegations include false statements about the drug candidate SLK's effectiveness compared to BIMZELX, specifically regarding its molecular targets and clinical benefits. This litigation allows affected investors until December 15, 2025, to seek appointment as lead plaintiff without incurring any costs.

Market Sentiment Analysis

CONCERNS & RISKS

  • MoonLake Immunotherapeutics faces a class action lawsuit for alleged securities fraud.
  • The complaint includes claims that the company's positive statements about its drug candidate SLK lacked a reasonable basis.
  • Allegations suggest misleading statements related to SLK's clinical benefits and characteristics compared to BIMZELX.

Full Press Release Details

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team:
MLTX investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) It's sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK’s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK’s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK’s purported superiority to monoclonal antibodies.
WHAT'S NEXT? If you suffered a loss in MoonLake during the relevant time frame, you have until December 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the MoonLake Immunotherapeutics lawsuit about?

The lawsuit addresses alleged securities fraud affecting MoonLake investors from March 10, 2024, to September 29, 2025.

Who can join the class action lawsuit?

Investors who suffered losses in MoonLake within the specified period can join the lawsuit.

What is the deadline to act on the lawsuit?

The deadline to request lead plaintiff status is December 15, 2025.

Will I have to pay to participate in the lawsuit?

No, class members may receive compensation with no out-of-pocket costs or fees.

Why choose Levi & Korsinsky for this case?

Levi & Korsinsky has a strong track record in securities litigation, securing significant recoveries for clients.

Last updated: Nov 6, 2025